Trial Profile
To evaluate prognostic impact of Ruxolitinib in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2018
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 18 Mar 2018 New trial record